Y
Yukiya Narita
Publications - 83
Citations - 795
Yukiya Narita is an academic researcher. The author has contributed to research in topics: Cancer & Internal medicine. The author has an hindex of 12, co-authored 62 publications receiving 511 citations.
Papers
More filters
Journal ArticleDOI
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS.
K. Muro,E. Van Cutsem,Yukiya Narita,Georgios Pentheroudakis,Eishi Baba,Jian Li,Min-Hee Ryu,W.I. Wan Zamaniah,W.P. Yong,K.-H. Yeh,Kyoko Kato,Zhihao Lu,Byoung Chul Cho,I.M. Nor,M. Ng,L.-T. Chen,Takako Eguchi Nakajima,Kohei Shitara,Hisato Kawakami,Takahiro Tsushima,Takayuki Yoshino,Florian Lordick,Erika Martinelli,Elizabeth C Smyth,Dirk Arnold,Hironobu Minami,Josep Tabernero,J.-Y. Douillard +27 more
TL;DR: These guidelines represent the consensus opinions reached by experts in the treatment of patients with metastatic oesophageal cancer representing the oncological societies of Japan (JSMO), China (CSCO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS).
Journal ArticleDOI
Regorafenib Versus Trifluridine/Tipiracil for Refractory Metastatic Colorectal Cancer: A Retrospective Comparison.
Toshiki Masuishi,Hiroya Taniguchi,Satoshi Hamauchi,Azusa Komori,Yosuke Kito,Yukiya Narita,Takahiro Tsushima,Makoto Ishihara,Akiko Todaka,Tsutomu Tanaka,Tomoya Yokota,Shigenori Kadowaki,Nozomu Machida,Takashi Ura,Akira Fukutomi,Masashi Ando,Yusuke Onozawa,Masahiro Tajika,Hirofumi Yasui,Kei Muro,Keita Mori,Kentaro Yamazaki +21 more
TL;DR: The results suggest that regorafenib and TAS‐102 have similar efficacy but different toxicities, which could guide the agent choice, which is unclear which drug should be administered first for refractory metastatic colorectal cancer.
Journal ArticleDOI
Neutropenia as a Predictive Factor in Metastatic Colorectal Cancer Treated With TAS-102.
Satoshi Hamauchi,Kentaro Yamazaki,Toshiki Masuishi,Yosuke Kito,Azusa Komori,Takahiro Tsushima,Yukiya Narita,Akiko Todaka,Makoto Ishihara,Tomoya Yokota,Tsutomu Tanaka,Nozomu Machida,Shigenori Kadowaki,Akira Fukutomi,Takashi Ura,Yusuke Onozawa,Masashi Ando,Masahiro Tajika,Kei Muro,Hirofumi Yasui,Keita Mori,Hiroya Taniguchi +21 more
TL;DR: Neutropenia may be a surrogate marker for adequate antitumor doses of TAS‐102 and be associated with better efficacy in patients with metastatic colorectal cancer.
Journal ArticleDOI
Prospective Survey of Financial Toxicity Measured by the Comprehensive Score for Financial Toxicity in Japanese Patients With Cancer
Kazunori Honda,Bishal Gyawali,Masashi Ando,Ryosuke Kumanishi,Kyoko Kato,Keiji Sugiyama,Seiichiro Mitani,Toshiki Masuishi,Yukiya Narita,Hideaki Bando,Hiroya Taniguchi,Shigenori Kadowaki,Takashi Ura,Kei Muro +13 more
TL;DR: Using the Japanese version of the COST tool, various factors associated with FT in Japanese patients with cancer are identified and will have important implications for cancer policy planning in Japan.
Journal ArticleDOI
Baseline Sarcopenia and Skeletal Muscle Loss During Chemotherapy Affect Survival Outcomes in Metastatic Gastric Cancer.
Keiji Sugiyama,Yukiya Narita,Seiichiro Mitani,Kazunori Honda,Toshiki Masuishi,Hiroya Taniguchi,Shigenori Kadowaki,Takashi Ura,Masashi Ando,Masahiro Tajika,Kei Muro +10 more
TL;DR: In this paper, the association between sarcopenia and prognosis in patients with metastatic gastric cancer (mGC) receiving chemotherapy was determined. But muscle loss during chemotherapy negatively affected survival among patients with mGC.